

Supplemental data

Suppl. Table 1. Reasons for hospitalization and onset of adverse events after end of blinatumomab treatment.


| Patient ID | Adverse event | Time to onset after end of blinatumomab treatment (d) |
|------------|-------------------------|---|
| 41 | Infectious diarrhea | 42 |
| 42 | Port infection | 30 |
| | Atrial fibrillation | 30 |
| | Cardiac decompensation | 34 |
| 44 | Pancreatitis | 14 |
| 62 | Fever of unknown origin | 10 |
| 66 | Sepsis | 122 |
| 69 | NSTEMI | 5 |
| | Aortic valve stenosis | 1367 |
| | Dyspnea | 1398 |
| | Cardiac insufficiency | 1581 |
| | Pneumonia | 1704 |
| 70 | Infectious diarrhea | 1224 |
| 72 | Preileus | 2967 |
| | Cholecystitis | 3151 |
| 74 | Pneumonia | 66 |
| | Dyspnea | 687 |
| 76 | Port infection | 345 |

Suppl. Table 2. Characteristics of patients evaluated by MoCA testing (n=9).

Scores on the MoCA range from zero to 30, with a score of 26 and higher generally being considered as normal. *Patient presented with slight impairment of visospatial cognition considered to be age-related rather than related to blinatumomab. AE, adverse event

| Patient ID | 66 | 67 | 68 | 70 | 72 | 73 | 74 | 75 | 76 |
|---|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Sex (m/f) | m | m | f | m | m | m | m | f | m |
| Age (y) | 43 | 42 | 52 | 62 | 70 | 68 | 58 | 64 | 66 |
| Prior systemic therapies (n) | 3 | 2 | 3 | 3 | 1 | 3 | 1 | 3 | 1 |
| Duration of blinatumomab treatment (d) | 57 | 58 | 15 | 57 | 35 | 57 | 57 | 56 | 57 |
| Max. dose ($\mu\text{g}/\text{m}^2/\text{d}$) | 60 | 60 | 60 | 60 | 60 | 90 | 60 | 60 | 60 |
| Neurological AE during treatment | X | | | | | X | X | | X |
| Responder (CR or PR) | X | X | | X | X | X | X | X | X |
| MoCA-Score | 28 | 28 | 30 | 26 | 21* | 26 | 30 | 30 | 26 |

Suppl. Figure 1



Legend to Suppl. Figure 1

Kaplan-Meier estimates for PFS with combined analysis of patients with relapsed or refractory FL, MCL or DLBCL as differentiated by histology who received blinatumomab. Abbreviations: FL, follicular lymphoma; MCL, mantle cell lymphoma; DLBCL, diffuse large B cell lymphoma; y, years.